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INTRODUCTION
Middle ear cholesteatoma is defined pathologically as the abnor-
mal existence of keratinized squamous epithelium in the middle 
ear. This disease results in the destruction in the adjacent bony 
tissue as a result of the interaction between hyperproliferative 
epithelial cells and subepithelial inflammatory cells, but the 
mechanism regulating the growth of cholesteatomas is not clear-
ly known. According to previous studies, the growth of middle 
ear cholesteatoma tissue is induced by various cytokines and 
growth factors secreted by inflammatory cells in the cholestea-
toma matrix and subepithelial tissue (1). Moreover, it is thought 
that various cytokines from activated immunologic cells can 
lead to neovascularization, which can further contribute to the 
growth of a cholesteatoma.
  Epidermal growth factor receptor (EGFR) is a 170 kDa trans-
membrane glycoprotein that is autophosphorylated by the bind-
ing of EGF. The subsequent biochemical reactions, such as phos-
phorylation of various target proteins, induce the growth of the 
cell (2). EGFR is known to be related to proliferation and differ-
entiation of normal cells in vivo. The relationship between 
EGFR expression and proliferation of neoplastic cells has been 
suggested by studies showing that the cytoplasmic portion of 
EGFR has the same structure as the ν-erb-B transforming onco-
gene and that EGFR is overexpressed in several cancer cells (3). 
Overexpression of EGFR has also been reported in middle ear 
cholesteatoma, suggesting that is also associated with the prolif-
eration of cholesteatomas. 
  It is well known that blood circulation is increased around the 
inflammatory tissue. Hyperproliferative tissue also requires an 
increase in blood supply. Cholesteatoma has both inflammatory 
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and hyperproliferative properties. There are many studies about 
angiogenesis in inflammatory tissue and many studies have re-
vealed that an increase in nutrients and oxygen supply plays an 
important role in the growth of neoplasms (4, 5). These facts 
suggest that the hyperproliferation of a cholesteatoma is related 
to neovascularization, and many studies on cholesteatoma have 
focused on angiogenesis and angiogenic factors (6, 7). 
  In this study, we evaluated the expression of EGFR and mi-
crovessel density (MVD) by immunohistochemical staining for 
CD31 and Factor VIII. Further, we characterized the relationship 
between the expression of EGFR and neovascularization in mid-
dle ear cholesteatoma tissue.
MATERIALS AND METHODS
We obtained cholesteatoma tissue from 32 subjects undergoing 
surgery as the study group, and normal postauricular skin tissue 
from 7 subjects as the control group. 
Immunohistochemical staining
Immunohistochemical staining was performed to evaluate the 
expression of EGFR and MVD. The tissues were fixed in 10% 
buffered neutral formalin solution and embedded in paraffin. 
For immunohistochemical staining, 4 μm-paraffin embedded tis-
sue sections were prepared on poly-L-lysine-coated slide (Sigma, 
St. Louis, MO, USA). The tissue sections were deparaffinized 
twice in 100% xylene for 10 minutes, and then treated with 
100%, 90%, 70%, and 30% ethyl alcohol for 10, 5, 5, and 5 
minutes, respectively, prior to rehydration with distilled water. 
The slides were then treated with 3% H2O2 in methanol for 10 
minutes and washed with distilled water for 5 minutes to quench 
endogenous peroxidase activity. Antigen retrieval was performed 
by heating the slides for 5 minutes in citrate buffer (pH 6.0) in a 
staining jar and by cooling for 20 minutes. Then, sections were 
washed twice with Tris-buffered saline (TBS, pH 7.6) for 5 min-
utes and left with blocking antibody at room temperature for 20 
minutes to remove nonspecific binding. After that, sections were 
incubated for 1 hour with 1:30 dilution of monoclonal antibody 
to EGFR, CD31 and Factor VIII (Novocastra, Newcastle, UK) in 
a wet chamber. After washing the sections three times with TBS 
for 5 minutes, we incubated the sections for 20 minutes at 37℃ 
with the secondary antibody, a biotinylated goat-anti mouse IgG 
(DAKO, Carpinteria, CA, USA), and then for an additional 20 
minutes with streptovidin-peroxidase conjugate (DAKO). After 
washing with TBS, 3,3'-diaminobenzidine tetrahydrochloride 
(DAB) was used to visualize the peroxidase activity and Mayer’s 
hematoxylin was used to counterstain. The sections were mount-
ed with Canada balsam. 
Quantitative analysis of EGFR expression
All specimens were independently analyzed by two pathologists 
who were blinded to the specimen information. Both the basal 
and suprabasal layers of the epitheliums of normal postauricular 
skin and cholesteatoma were analyzed for positive staining. 
  The EGFR positive-staining rates were determined in the ar-
eas where the full thickness of the epidermis could be clearly 
seen, and we designated cells that stained brown in the cyto-
plasm or membrane as positive. The results for the specimen 
training were recorded as negative (-) if the percentage of posi-
tive cells was under 10%, weakly positive (+) if 11-30%, moder-
ately positive (++) if 31-60%, and strongly positive if over 60%. 
After the identification of well-stained areas under a light mi-
croscope at 100-fold magnification, we calculated the average 
percentage of three different spots at 400-fold magnification.
Calculation of MVD by immunohistochemical staining of CD31 
and Factor VIII
In the areas of brown staining for microvessels (venule and cap-
illaries) observed under a light microscope at 100-fold magnifi-
cation, we calculated the average numbers of microvessels in 
three different areas at 200-fold magnification.
Statistical analysis
Fisher’s exact test, Mann-Whitney U-test and Spearman correla-
tion test were applied for the statistical analysis using SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA) program, and a P-value<0.05 
was defined as a statistically significant difference.
RESULTS
Expression of EGFR
Among 7 normal postauricular skin samples, there was no de-
tectable expression of EGFR in 5 samples. In cholesteatoma, 
EGFR staining was weakly positive in 11 samples, moderately 
positive in 9 samples, strongly positive in 4 samples, and not de-
tected in 8 samples (Fig. 1, Table 1). 
  We analyzed the expression of EGFR by separating the epithe-
lium into suprabasal and basal layers. In the basal layer, 5 nega-
tive, 1 weakly positive, 1 moderately positive and 0 strongly 
positive cases were detected in the postauricular skin, and 16 
negative, 9 weakly positive, 5 moderately positive and 2 strongly 
positive cases were found in the cholesteatoma group. The two 
groups were composed mostly of either negative or weakly posi-
tive cases, and there were no significant difference between the 
two groups (P=0.895). 
  In the suprabasal layer, 5 negative cases, 1 weakly positive case, 
0 moderately positive cases and 1 strongly positive case were 
detected in the postauricular skin, and 6 negative, 13 weakly 
positive, 9 moderately positive and 4 strongly positive cases were 
detected in the cholesteatoma samples. Most of the postauricu-
lar skin group stained negatively, but cholesteatoma group had 
more moderately and strongly positive cases, and these differ-Jin BJ et al.: EGFR and microvessel density in cholesteatoma    69
ences in staining were statistically different between the two 
groups (P=0.029) (Table 2).
MVD
The MVD was analyzed using CD 31 staining in the two groups. 
We found 14.14±4.34 in postauricular skin and 27.63±13.21 
in cholesteatoma (P=0.004) (Fig. 2). Using Factor VIII staining, 
MVD was 8.71±4.03 in the postauricular samples and 18.97±
8.87 in the cholesteatoma samples (P=0.002) (Fig. 3). Thus, the 
MVD was significantly higher in the cholesteatoma samples, re-
gardless of the staining method used (Table 3).
  The correlation between CD31 and Factor VIII staining was 
statistically significant (coefficient of correlation, 0.814; P<0.001) 
(Fig. 4).
Correlation between the expression of EGFR and MVD
For the analysis of a correlation between the expression of EGFR 
and MVD, we divided the expression of EGFR into two groups, 
the weakly expressed group (negative or weak positive) and the 
highly expressed group (moderate to strong positive). MVD us-
ing CD31 was 20.37±10.82 in the weakly expressed group and 
38.23±8.37 in the highly expressed group, which is a statistical-
ly significant difference (P<0.001). MVD using Factor VIII was 
15.00±7.00 in the weakly expressed group and 24.77±8.26 in 
the highly expressed group, representing a statistically significant 
difference (P=0.002) (Table 4).
Table 1. Comparison of epidermal growth factor receptor (EGFR) ex-
pression in cholesteatoma and postauricular skin 
Postauricular skin 
(%)
Cholesteatoma 
(%)
P-value*
EGFR  -  5 (72) 8 (25) 0.203
+  1 (14) 11 (34)
++  1 (14) 9 (28)
+++  0 (0) 4 (13)
*Fisher’s exact test.
Table 2. Comparison of epidermal growth factor receptor (EGFR) 
expression in the basal and suprabasal layer of cholesteatoma tis-
sue and postauricular skin  
Basal layer Suprabasal layer
Postauricular 
skin (%)
Cholesteato-
ma (%)
Postauricular 
skin (%)
Cholesteato-
ma (%)
EGFR  -  5 (72) 16 (50) 5 (72) 6 (19)
+  1 (14) 9 (28) 1 (14) 13 (41)
++  1 (14) 6 (19) 0 (0) 9 (28)
+++  0 (0) 1 (3) 1 (14) 4 (12)
P-value*  0.895 0.029
*Fisher’s exact test.
Table 3. Microvessel density by immunohistochemical staining of 
CD31 and Factor VIII in cholesteatoma and postauricular skin   
CD31 Factor VIII
Cholesteatoma (n=32)  27.63±13.21 18.97±8.87
Postauricular skin (n=7)  14.14±4.34 8.71±4.03
P-value*  0.004 0.002
*Mann-Whitney U-test.
Fig. 2. Immunohistochemical demonstration of microvessel density 
using anti-CD31 antibody in a cholesteatoma (A) and postauricular 
skin (B) (×200). Cholesteatoma tissue shows high microvessel den-
sity, but postauricular skin shows low microvessel density.
A B
Fig. 3. Immunohistochemical demonstration of microvessel density 
using anti-Factor VIII antibody in a cholesteatoma (A) and postau-
ricular skin (B) (×200). Cholesteatoma tissue shows high microves-
sel density, but postauricular skin shows low microvessel density.
A B
Fig. 1. Immunohistochemical demonstration of epidermal growth fac-
tor receptor in cholesteatoma (×400). Negative (A), weakly positive 
(B), moderately positive (C) and strongly positive (D) findings.
A
C
B
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DISCUSSION
EGFR is a 170 kDa transmembrane glycoprotein composed of 
an intracellular tyrosine kinase domain, extracellular ligand-
binding domain and transmembrane domain. The binding of 
EGF to the extracellular domain induces the activation of tyro-
sine kinase, which initiates a signal transmission pathway that 
induces cell proliferation by expression of transcription factors 
like c-jun and c-fos in the nucleus (8). Also, the structural non-
discrimination between the cytoplasmic portion of EGFR and 
ν-erb-B transforming oncogene is evidence of an important role 
for EGFR in regulation of growth in both normal and abnormal 
cells (9). EGFR is normally expressed in all kinds of cells from 
the germinal layer, and it is expressed highly in gastrointestinal 
tract and the urogenital tract. The overexpression of EGFR has 
been reported for various diseases such as psoriasis, and in hy-
perproliferating such as skin cancer (10), brain cancer (11) and 
head and neck cancer (12). Also, it has been reported that EGFR 
is overexpressed in cholesteatoma. Some studies have reported 
the overexpression of EGFR in both the basal and suprabasal 
layer (13), but other studies have reported overexpression of 
EGFR in only the suprabasal layer (14). 
  In this study, the overall expression of EGFR is higher in cho-
lesteatoma than in postauricular skin, but the difference in ex-
pression is not statistically significant. In our analysis in which 
the epithelium was separated into a basal and suprabasal layer, 
cholesteatoma showed higher EGFR expression than postauric-
ular skin in the suprabasal layer. Thus, it is thought that hyperp-
roliferation is a characteristic of cholesteatomas. 
  Many studies have reported on the importance of the interac-
tion between the epithelium and connective tissue (the dermis 
of normal skin and matrix of cholesteatoma) in proliferation and 
differentiation. In cholesteatomas, the interaction between the 
epithelium and matrix produces various cytokines and growth 
factors, which induce proliferation, differentiation, and neovas-
cularization of the cholesteatoma (15, 16). Many studies have 
reported the neovascularization in the cholesteatoma, and have 
uncovered the correlation between cholesteatoma and the ex-
pression of angiogenic factors such as β-fibroblast growth factor 
(FGF), FGF-2 and vascular endothelial growth factor (VEGF). 
Sudhoff et al. (7) reported that the expression of angiogenic fac-
tors such as β-FGF, TGF (transforming growth factor)-α, TGF-β1 
and VEGF in cholesteatoma was 4.3 fold higher than in the mid-
dle ear mucosa and twice more than in the external auditory 
canal skin. They also detected more neovascularization in more 
severely inflamed tissue in cholesteatoma, so they concluded 
that neovascularization could have an important role in inflam-
mation and inflammatory reactions in cholesteatoma. Stamm-
berger et al. (17) conducted a morphological analysis of the 
newly developed vessels in cholesteatoma using Factor VIII, and 
revealed more neovascularization than in the dermis of normal 
skin. Hyperproliferative tissue like middle ear cholesteatoma re-
quires more vascularization, and the neovascularization is thought 
to contribute to the migration of the epithelium of cholesteato-
ma into the middle ear. So, it has been suggested that the matrix 
of cholesteatoma can invade the middle ear by this composite 
action.
  For the morphological observation of the MVD, the surface 
antigens of the vascular endothelium such as CD34, CD31 and 
Factor VIII were used. This study used Factor VIII and CD31. In 
general, CD31 reacts to the endothelial cells of the blood vessel, 
and Factor VIII reacts to the endothelial cells of the blood and 
lymphatic vessels (18). A cholesteatoma also has lymphatic tis-
sue in the matrix and surrounding tissues, and initially this study 
intended to identify MVD and microlymphatics density using 
both CD31 and Factor VIII. It is assumed that subtraction of 
MVD using CD31 from the microvessel plus microlymphatics 
densities using Factor VIII in the same section could reveal the 
microlymphatics density. But our results showed less density in 
Factor VIII staining than in CD31 staining. We thought that Fac-
tor VIII was less expressed in cholesteatoma tissue than CD31. 
Although the correlation between the Factor VIII and CD31 
suggested that these factors would be useful in the identification 
Fig. 4. Correlation between CD31 and Factor VIII. A positive correla-
tion between CD31 and Factor VIII was identified. The correlation ef-
ficient was 0.814 (by Spearman correlation test) with a P<0.001.
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Table 4. Correlation between epidermal growth factor receptor 
(EGFR) and CD31 in cholesteatoma  
CD31 Factor VIII
EGFR  -/+ (n=19)  20.37±10.82 15.00±7.00
++/+++ (n=13)  38.23±8.37 24.77±8.26
P-value*  <0.001 0.002
*Mann-Whitney U-test. Jin BJ et al.: EGFR and microvessel density in cholesteatoma    71
of MVD, Factor VIII is less expressed in cholesteatoma tissue, so 
it is thought that CD31 is more useful. This study revealed statis-
tically higher MVD than in postauricular skin, and this result 
corresponds to the results of the study of Stammberger et al. 
(17) or Anniko and Mendel. (19). 
  Up until now, there have only been a few studies directly 
demonstrating the correlation between growth factor and neo-
vascularization in cholesteatoma. Stammberger et al. (20) report-
ed a significant correlation between growth factor TGF-α and 
MVD using Factor VIII, and Sudhoff et al. (21) reported that the 
growth of the epithelium and vascular endothelium was increased 
with the inflammatory reaction of the cholesteatoma. In this 
study, the more the expression of EGFR increased, the higher 
the MVD was in both basal and suprabasal layers of the choles-
teatoma. 
  In conclusion, MVD using CD31 and Factor VIII was signifi-
cantly higher in a cholesteatoma than in postauricular skin, and 
the MVD was significantly correlated with the expression of 
EGFR. The overexpression of EGFR in the middle ear cholestea-
toma might be closely related to the neovascularization, and it 
is thought that overexpression of EGFR and neovascularization 
are correlated with the growth of a cholesteatoma.
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